Decorin and MRI markers to predict response to anti-VEGF treatment in recurrent glioblastoma
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma
This project looks at whether a protein called decorin and a type of MRI (diffusion MRI) can help predict which people with recurrent glioblastoma will benefit from anti-VEGF therapy like bevacizumab.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11305218 on NIH RePORTER |
What this research studies
This project combines diffusion MRI scans and measurements of the protein decorin from tumor tissue or blood in people with recurrent glioblastoma. Researchers will compare MRI apparent diffusion coefficient (ADC) patterns and decorin levels with how patients do after anti-VEGF treatment such as bevacizumab. The work will use existing patient data and prospectively collected imaging and samples to link these markers with survival and treatment response. The goal is to develop markers that help guide treatment choices and identify patients for future trials.
Who could benefit from this research
Good fit: People with recurrent glioblastoma who are being considered for anti-VEGF therapy and can undergo diffusion MRI and provide tumor tissue or blood samples.
Not a fit: People with newly diagnosed glioblastoma, those not receiving anti-VEGF therapy, or those unable to have MRI or provide samples may not benefit from this work.
Why it matters
Potential benefit: If successful, this could help doctors identify which patients are likely to benefit from anti-VEGF therapy and avoid ineffective treatments.
How similar studies have performed: Previous analyses of over 400 patients across multiple trials suggest diffusion MRI (high ADC) predicts better response to anti-VEGF therapy, while using decorin as an added biomarker is a newer approach with less prior testing.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Ellingson, Benjamin M. — University of California Los Angeles
- Study coordinator: Ellingson, Benjamin M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.